Model organisms have emerged as suitable and reliable biological tools to study the properties of proteins whose function is altered in human disease. In the case of the PI3K and PTEN human cancer-related proteins, several vertebrate and invertebrate models, including mouse, fly, worm and amoeba, have been exploited to obtain relevant functional information that has been conserved from these organisms to humans along evolution. The yeast Saccharomyces cerevisiae is an eukaryotic unicellular organism that lacks a canonical mammalian-like PI3K/PTEN pathway and PIP3 as a physiological second messenger, PIP2 being essential for its life. The mammalian PI3K/ PTEN pathway can be reconstituted in S. cerevisiae, generating growth alteration phenotypes that can be easily monitored to perform in vivo functional analysis of the molecular constituents of this pathway. Here, we review the current nonmammalian model systems to study PTEN function, summarize our knowledge of PTEN orthologs in yeast species and propose the yeast S. cerevisiae as a sensitive biological sensor of PI3K oncogenicity and PTEN tumor suppressor activity.
The PTEN protein, encoded by a single gene in mammalian species, is the major enzyme that counteracts signaling by the distinct proto-oncogenic PI3Ks, converting the PI3K product, PtdIns(3,4,5)P 3 (PIP3), to PtdIns(4,5)P 2 (PIP2). The conservation of PTEN aminoacid sequence in vertebrates is very high, ranging from nearly 100% identity between primates and rodents to 80% identity between primates and teleost fish (Table 1; Figure 1a ; see Figure 2 for a depiction of PTEN domains). Many mice strains have been generated, including PTEN-knockout, -conditional knockout and -transgenic mice, that constitute excellent mammalian animal models to study the role of PTEN in human cancer and to validate PTEN-related anticancer therapies (Kishimoto et al., 2003; Chow and Baker, 2006; Tamguney and Stokoe, 2007; Pulido and van Huijsduijnen, 2008; Suzuki et al., 2008) . PTEN studies have also been performed in other vertebrates, including amphibia and fish. In frogs (Xenopus laevis), PTEN activity is required for cell cycle elongation associated with morphogenesis during embryo gastrulation, and changes in plasma membrane and nuclear localization of PTEN, likely reflecting changes in PTEN activity, were found during early embryogenesis of this organism (Ueno et al., 2006) . Zebrafish (Danio rerio) contains two highly related PTEN genes, zPTENa and zPTENb, each of them producing a short and a long splice variant. Compared with mammalian PTEN, zPTENa contains an extra amino-acid sequence at the C2 domain. In addition, the long splice variants from both zPTEN genes possess a further exon encoding for another extra sequence, also at the C2 domain (Croushore et al., 2005) . The functional properties of these isoform-and fish-specific regions are unknown, although the in vitro activity against PIP3 seems to be lower for zPTENb than for zPTENa (Faucherre et al., 2008) . Antisense knockdown of zPTENa or zPTENb has been reported to produce distinct, nonredundant developmental abnormalities during zebrafish embryogenesis (Croushore et al., 2005) . However, zPTENa À/À or zPTENb À/À single mutants did not display embryonic phenotypes, whereas double zPTENa À/À and zPTENb À/À mutants displayed early embryonic lethality associated with hyperplasia, which could be ameliorated by embryo exposure to the PI3K inhibitor LY294002. In addition, zPTENb À/À animals developed spontaneous eye tumors late in life, suggesting that zPTENb plays tissue-specific-, nonredundant tumor suppressor functions in zebrafish (Faucherre et al., 2008) .
PTEN orthologs in invertebrates possess both a PTP and a C2 domain with high similarity (especially at the PTP domain) to mammalian PTEN. However, the conservation of the regulatory PTEN C-terminal region in invertebrates with respect to vertebrates is weak. Remarkably, in the fruit fly Drosophila melanogaster, the PTEN gene generates three alternatively spliced isoforms, which differ in their C-terminus (dPTEN1, dPTEN2 and dPTEN3) (Smith et al., 1999) . Two of these isoforms only differentiate by the presence (dPTEN2) or the absence (dPTEN3) of a C-terminus PDZ domain-binding motif. Alternatively spliced products of human PTEN that affect its C-terminus have also been documented, although they are expected to be destabilized, resulting in lack of function (Sharrard and Maitland, 2000) . The three spliced forms of dPTEN dephosphorylate PIP3 in vitro. However, dPTEN2, that interacts with the PDZ3 domain of the scaffolding protein Bazooka/PAR-3 (von Stein et al., 2005; Pinal et al., 2006) , was unable to downregulate dAkt activation in cells (Maehama et al., 2004) . This is in contrast with mammalian PTEN, whose PDZ domainbinding motif favors PTEN activity in cells by interaction with stabilizing and/or plasma membrane-targeting proteins (Wu et al., 2000a, b; Valiente et al., 2005) . Whether this difference is due to different patterns of PDZ domains interactions or to distinct intrinsic functional requirements for mammalian and Drosophila PTEN remains unexplored. Noticeably, the PDZ2 domain of Bazooka/PAR-3 binds to phosphoinositides, which may account for specific outputs in the signaling mediated by Bazooka/PAR-3-PTEN complexes (Wu et al., 2007) . Genetic study in Drosophila has largely contributed to the studies of PI3K signaling and oncogenesis (Hariharan and Bilder, 2006) . As for vertebrates, homozygous mutation of dPTEN results in early embryonic lethality as a consequence of the overactivation of the Drosophila insulin/PI3K/Akt pathway, producing hyperplastic growth and increased cell and organ size. Overexpression of dPTEN also causes lethality in embryos, likely by cell cycle and cell growth inhibition, as well as by an excess of apoptosis. In addition, upon eye-specific overexpression, dPTEN caused a small eye phenotype (Goberdhan et al., 1999; Huang et al., 1999; Gao et al., 2000; Scanga et al., 2000; Stocker et al., 2002) . Whether mammalian PTEN is also able to induce this small eye phenotype upon targeted overexpression in flies remains controversial (Huang et al., 1999; Song et al., 2007) . It is likely that mammalian and Drosophila PTEN have distinct requirements for tissue-specific physiologic activities.
The PTEN gene product in the nematode Caenorhabditis elegans, DAF-18, is also directly linked to the negative regulation of signaling through the insulin/ PI3K/Akt pathway, which controls metabolism, dauer formation during larvae development and longevity in this organism. DAF-18 mutation is not lethal but causes secondary phenotypes, including reproductive defects and shorter lifespan. DAF-18 mutants fail to form dauers under overgrowth or starvation conditions, or on genetic backgrounds (insulin receptor-like or PI3K-like mutants) that cause constitutive dauer formation (Ogg and Ruvkun, 1998; Gil et al., 1999; Mihaylova et al., 1999; Rouault et al., 1999; Masse et al., 2005; Solari et al., 2005) . Also, DAF-18 mutants are defective in the prefeeding growth arrest at the first stage of C. elegans larvae development, resulting in inappropriate germline growth (Fukuyama et al., 2006) . These genetic findings . In the social amoeba Dictyostelium discoideum, PTEN is involved in the regulation of chemotaxis and motility to cAMP gradients. PTEN-mutated Dictyostelium cells show defects in the chemotactic response, involving speed, cell polarity and pseudopod formation, as a result of the disorganization of PIP3 local gradients in the plasma membrane of the anterior and posterior regions of the cell (Funamoto et al., 2002; Iijima and Devreotes, 2002; Chen et al., 2007; Hoeller and Kay, 2007; Wessels et al., 2007) . Noticeably, in mammalian cells responsive to chemotactic stimuli, both positive and negative roles for PTEN in chemotaxis have been described, depending on the cell type (Fox et al., 2002; Lacalle et al., 2004; Gao et al., 2005; Subramanian et al., 2007; Wan et al., 2007) . Furthermore, in mouse neutrophils, the SHIP1 5-phosphatase (that also has PIP3 as a substrate), but not PTEN, has been found to be the major regulator of polarization and motility (Nishio et al., 2007) . Thus, mammalian cells may follow cell type-and/or chemoattractant-specific patterns of chemotaxis regulation, including PTEN-independent chemotactic responses. As for DAF-18, PTEN from D. discoideum contains an unique C-terminal region of unknown function, whereas the regulatory N-terminal PIP2-binding motif is functionally conserved (Maehama et al., 2001; Iijima et al., 2004) . The A. thaliana genome contains three putative PTEN-like genes, AtPTEN1, -2 and -3. AtPTEN2 and AtPTEN3 are large highly related proteins, whose activity and function have not been tested yet. All PTEN from metazoans listed in Table 1 contain an identical P-loop core signature (IHCKAGKGRT), whereas AtPTEN1 contains a slightly divergent P-loop (VHCMAGKGRT) and has been shown to have phosphatase activity in vitro against P-Tyr and PIP3 (Gupta et al., 2002) . AtPTEN1 is expressed specifically in pollen, and silencing of AtPTEN1 caused abnormal pollen development in the form of collapsed, shrunken and small pollen grains. Remarkably, no plant class I PI3Ks have been identified, and there is no evidence of the existence of PIP3 in plants, suggesting that the physiologic substrates for PTEN-like enzymes in plants could be different.
In sum, multiple nonmammalian model organisms are available to study PTEN function, based on the general conservation of the signaling PI3K-dependent module. Nonetheless, technical caveats emerge if large-scale genetic analyses are planned in most of the systems described above. These problems have led researchers in A yeast model to assess PTEN tumor suppressor activity VJ Cid et al Figure 2 (a) Schematic depiction of functional domains on PTEN (H. sapiens), Ptn1 (Sch. pombe), and Tep1 (S. cerevisiae). Amino-acid numbering of domains is indicated, according to entries given in Table 1 . Dotted squares in PTEN indicate unstructured regions, which are absent in the resolved crystal structure (Lee et al., 1999) . The amino-acid sequences of the catalytic signature motifs are shown. Ptn1, but not Tep1, possesses a consensus PIP2-binding motif (L/R-X 4 -L/R-X-L/R-L/R) at its N-terminus. The C2 domain and the PDZ domainbinding motif are absent from both Ptn1 and Tep1. The PTP domain of Tep1 possesses an unique region (residues 97-148) and a catalytic signature motif with divergent amino-acid sequence (residues in red). (b) Alignment of the amino-acid sequences of the PTP domains from PTEN, Ptn1 and Tep1. Alignment was made by ClustalW. Identical residues are highlighted, and the catalytic WPD-, P-and TI-loops are indicated. '*' means that the residues or nucleotides in that column are identical in all sequences in the alignment. ':' means that conserved substitutions have been observed. '.' means that semiconserved substitutions are observed. Amino-acid identity by BLASTP alignment (PTP domains): human/Sch. pombe, 37%; human/ S. cerevisiae, 27%; Sch. pombe/S. cerevisiae, 29%).
A yeast model to assess PTEN tumor suppressor activity VJ Cid et al the last decades to explore the feasibility and ease of handling of unicellular eukaryotic organisms, such as yeasts.
The PI3K/PTEN pathway in fission and budding yeasts: just a missing link?
Both the budding yeast Saccharomyces cerevisiae and the fission yeast Schizosaccharomyces pombe have been widely exploited as single eukaryotic cell models. Most basic signaling pathways, such as those involving CDKdependent cell cycle regulation, G protein-coupled receptors and MAPK pathways, for instance, have been thoroughly studied in yeasts. Conclusions derived from signaling studies in these model organisms have proved, in general, relevant for our understanding of their counterparts in mammalian cells. However, lipid signaling through PIP3 may be an exception to this rule. In contrast to the key role of PIP3 as a second messenger in higher eukaryotes, neither class I PI3K activity nor genes coding for putative orthologs have been found in yeasts. Nevertheless, the role of other phosphoinositides is well documented in these organisms, especially in the budding yeast, where many studies have contributed to elucidate the involvement of PIP2 in actin cytoskeleton remodeling, or monophosphorylated PtdIns(3)P and PtdIns(4)P in trafficking and secretion (Strahl and Thorner, 2007) . In this context, it was surprising to find that both S. cerevisiae and Sch. pombe encode in their respective genomes a putative PTEN ortholog, respectively the TEP1 and ptn1 gene products (Li et al., 1997; Mitra et al., 2004) (Figure 2 ), as well as orthologs to classic mammalian PIP3 targets such as the AGC kinases PDK1 and PKB/Akt (Figure 3 ). Furthermore, mTor orthologs, now considered a key downstream effector of PI3K-dependent signaling in higher eukaryotes, were actually first uncovered in yeast (Kunz et al., 1993; Lorenz and Heitman, 1995) . Very little is known about the function of PTEN yeast orthologs, whose similarity with mammalian PTEN is restricted to the PTP catalytic domain (Table 1 ; Figure 2 ). In fission yeast, Mitra et al. (2004) Figure 3 Conservation of the components of mammalian PIP3-dependent pathways in yeasts. (a) In mammalian cells, PIP3 generated by class I PI3K locally recruits the PH domain-containing protein kinases PDK1 and PKB/Akt. PDK1 targets and activates Akt and SGK kinase. Full Akt activation requires phosphorylation of its Cterminal domains by the TORC2 kinase complex. Among its multiple targets, Akt phosphorylates the TSC1-TSC2 complex, allowing the small GTPase RheB to activate the TORC1 kinase, a key regulator of protein synthesis. By this means, PIP3 generation is a key step for cellular proliferation and tumor progression. PTEN, by counteracting the effect of PI3K, constitutes the major downregulator of this pathway. (b) Sch. pombe lacks class I PI3K, but expresses putative orthologs of mammalian PTEN (Ptn1), PDK1 (Ksg1), Akt (Sck2), SGK (Gad8) and both TORC complexes. PIP3, although existing, has not been to date involved as a second messenger signaling towards any of these kinases. The Gad8 kinase is phosphorylated in conserved activation sites by both Ksg1 and SpTORC2. TORC1 function in the control of protein translation, as well as its regulation by the TSC pathway, are conserved from fission yeast to mammals, but no evidence that AGC kinases act upstream SpTORC1 has been provided so far. (c) In S. cerevisiae no PIP3 has been yet detected. PIP2, by interaction with PH domain-containing proteins, works in a complex signaling network that also involves the TORC2 complex, sphingolipid long-chain bases (LCB)-dependent PDK1 orthologs Pkh1 and Pkh2 and SGK orthologs Ypk1 and Ypk2. This network regulates actin cytoskeleton assembly in response to stress, as well as cell wall integrity (CWI) and endocytosis. Sch9, considered a putative Akt or S6K ortholog, performs multiple functions, including the regulation of protein synthesis in response to stress through TORC1. Thus, TORC1 function seems conserved in budding yeast, but not its regulation. The PTEN ortholog, Tep1, has not been related to any of these functions. similar in vitro substrate specificity for Ptn1 as compared with mammalian PTEN, suggesting that it should work in vivo as a phosphoinositide phosphatase. Indeed, deletion of Sch. pombe ptn1 yielded detectable PIP3 levels, an important finding that led the authors to conclude that alternative PIP3 biosynthetic pathways exist in fungi that involve the concourse of class III PI3K (Vps34) before PI 5-kinases. Such alternative PIP3 biosynthetic route has been also described in mammalian cells (Zhang et al., 1997) . To date, both the biological meaning of PIP3 pools and the biological function of Ptn1 in Sch. pombe remain unknown, although several lines of evidence point towards a role in membrane dynamics and trafficking: first, cells deleted for ptn1 have an abnormal vacuolar morphology; and second, a Ptn1-GFP fusion localized to cytoplasmic membranous compartments and septa (Mitra et al., 2004) . In S. cerevisiae there is no direct evidence, either in vivo or in vitro, that the PTEN ortholog Tep1 acts as a phosphoinositide phosphatase. The facts that TEP1 gene expression is enhanced during sporulation and that diploid tep1/tep1 mutants develop spores with a defective cell wall, entail a role in spore formation. Interestingly, a mutation mimicking PTEN G129E, which implies a loss of catalytic activity on lipid substrates (Tep1-G199E) caused the same sporulation defects as a deletion of the gene, suggesting that dephosphorylation of phosphoinositides is crucial for the function of Tep1 (Heymont et al., 2000) . Localization of Tep1-GFP is reminiscent of that of Ptn1 in cytoplasmic spots, but Tep1 does not decorate the septum area in S. cerevisiae (Rodrı´guez-Escudero et al., 2005) . Thus, PTEN orthologs may play common as well as specialized roles in divergent fungal species. A search for PTEN orthologs in fungal species that have their sequence deposited in genomic databases reveals that PTEN is an ubiquitous gene in fungi, supporting an important role for its protein product. Figure 1b provides a phylogenetic tree based on the alignment of the PTEN/Tep1/Ptn1 predicted proteins from representative species of yeast, dimorphic and filamentous fungi. The essential residues in the catalytic P-loop signature motif are conserved in these organisms with respect to metazoans, as well as essential residues in the WPD-and TI-loops. However, a cluster of yeast species within the Saccharomycetales order, including S. cerevisiae, possess a distinctive catalytic P-loop ((I/V/L)HC(R/K) MGKGR) and a variable insertion in the vicinity of the WPD-loop region (Figures 1b and 2 ), suggesting specific substrate specificity and/or physiological substrates.
Many of the major effectors downstream PIP3 in mammals are present in yeast cells. In higher cells, the transducers of PIP3 signaling are protein kinases that recognize this lipid by a specific PH domain, namely PDK1, and its activation target, PKB/Akt. PIP3 generation by PI3K upon the proper stimulus at cellular membranes brings into proximity Akt and PDK1, triggering phosphorylation events that lead to the downstream activation of the mTor kinase complex 1 (TORC1), a key regulator of protein synthesis. For full activation, in addition to phosphorylation of the activation loop by PDK1, Akt requires a second phosphorylation in its C-terminal hydrophobic motif, which is performed by mTor itself as part of a different complex (TORC2) (Figure 3a ) (Hanada et al., 2004; Bhaskar and Hay, 2007) . The existence of bona fide PDK1 homologs in both budding and fission yeast has been reported (Casamayor et al., 1999; Niederberger and Schweingruber, 1999) . The redundant Pkh1 and Pkh2 proteins from S. cerevisiae play important roles in the control of endocytosis, actin cytoskeleton organization and activation of protein kinase C (Pkc1) signaling (Inagaki et al., 1999; Sun et al., 2000; Friant et al., 2001; Liu et al., 2005a; Walther et al., 2007) . Similar to their mammalian ortholog, PDK1, Pkh1/2 phosphorylate and activate a second pair of redundant kinases, Ypk1 and Ypk2, that are AGC kinases related to mammalian SGK (50-52% identity) (Casamayor et al., 1999; Roelants et al., 2002) and S6K (47-48% identity). Instead of responding to PIP3, the lipid messengers involved in the modulation of the budding yeast AGC kinases are sphingoid long-chain bases, such as phytosphingosine (Friant et al., 2001; Liu et al., 2005b) . In fission yeast, however, the PDK1 ortholog Ksg1, that also phosphorylates the SGK/S6K Sch. pombe ortholog Gad8 (Matsuo et al., 2003) , has a PH domain in its primary sequence, so it might respond to phosphoinositides. PH domains, especially those that target PIP2 are common in both budding and fission yeast proteins related to cytoskeletal function. Some of them have been shown to bind PIP3 as well in vitro, although none has shown high specificity for binding to this lipid compared with PIP2 (Mitra et al., 2004; Yu et al., 2004) .
A putative Akt ortholog in the budding yeast is the Sch9 protein kinase, involved in multiple functions, including aging, nutrient sensing and stress response (Fabrizio et al., 2001; Pedruzzi et al., 2003; Kaeberlein et al., 2005; Roosen et al., 2005; Pascual-Ahuir and Proft, 2007) . Sch9 has been reported to be an in vitro substrate for Pkh1, consistently with a conservation of a PDK1-Akt signaling module in yeast. However, such module would rely again on long-chain bases instead of phosphoinositides, as Sch9, like Pkh1/2, responds to sphingolipid levels (Liu et al., 2005b) . In addition, Sch9 has been recently discovered as a phosphorylation target for the TORC1 complex, instead of the TORC2 complex as it would be expected for an Akt ortholog. This would functionally relate Sch9 to the S6K AGC kinase rather than to Akt. In fact, the yeast Tor1-Sch9 pathway regulates ribosome biogenesis and translation initiation in a conserved manner, as compared with mammalian TORC1-S6K (Urban et al., 2007) . Thus, Sch9 may play multiple roles that are reminiscent of those of different AGC kinases in mammalian cells. The Akt-dependent activation of TORC1 by inhibitory phosphorylation of TSC2 (tuberous sclerosis complex), a negative regulator of the small GTPase Rheb, does not seem to be conserved in yeast. In fact, there are no discernable TSC-coding genes in the budding yeast genome. Although Sch. pombe possesses orthologs of this pathway, there is no evidence to date that TORC1 and TSC orthologs may act downstream of any of the fission yeast AGC kinases, including Sgk2, a putative functional ortholog to Sch9 (Roux et al., 2006) . In summary, as illustrated in Figure 3 , the yeast AGC kinase-related modules contribute to signaling networks that balance growth and survival signals in response to nutrients and environmental conditions. Despite of the lack of significant signaling through PIP3 in the yeast cell, many components of the PIP3-dependent higher eukaryotic pathways are conserved in lower eukaryotes. Nevertheless, unlike in higher cells, they do not seem to be linked in a linear PI3K-Akt-TORC1-like pathway and, remarkably, different lipidic second messengers are involved.
S. cerevisiae as a biological sensor of PI3K oncogenicity and PTEN tumor suppressor function
In addition to the widespread use of the yeast model for the elucidation of conserved eukaryotic functions, including key molecular mechanisms related to oncogenesis, the expression in yeast of mammalian genes related to disease can be a rewarding complementary strategy for their study (Mager and Winderickx, 2005) . Expression of the catalytic subunit of mammalian class I PI3K (p110a) in S. cerevisiae was first used to identify PIP3-specific mammalian PH domains, where no toxicity of the heterologous kinase for the yeast system was reported (Isakoff et al., 1998) . Overexpression of human p110a from the strong galactose-inducible promoter GAL1 was reported to be toxic in a systematic study on the expression of human cDNAs in yeast (Tugendreich et al., 2001) . Toxicity of p110a in yeast is dramatic when the protein is targeted to membranes by means of a C-terminal fusion to a CAAX prenylation box and expressed from the GAL1 promoter (Rodrı´-guez-Escudero et al., 2005) . The protein lacking the CAAX signal in the same expression system is not toxic in yeast, but growth is impaired when gain-of-function oncogenic mutants, such as p110a-H1047R, are expressed. This proves that the yeast cell is sensitive to changes in the catalytic activity of p110a, which can reflect clinically relevant pathogenic mutations in the PIK3CA gene. Toxicity in yeast by hyperactive p110a is concomitant to conversion of its essential PtdIns(4,5)P 2 plasma membrane pools to PtdIns(3,4,5)P 3 leading to actin and septin cytoskeleton disassembly. The p110b PI3K catalytic subunit, when expressed in yeast, generates less amount of PIP3 and is less toxic than p110a, even when fused to a -CAAX box (Andre´s-Pons et al., 2007) . Both PIK3CA and PIK3CB genes are amplified in tumors, but only the PIK3CA gene has been found to be targeted by gain-of-function mutations (Karakas et al., 2006; Vogt et al., 2007) . It seems that p110a is a more robust enzyme in yeast than p110b, which may resemble its functional intrinsic activity in mammals (Funaki et al., 1999; Beeton et al., 2000) . Coexpression of GFP-tagged mammalian Akt1 in yeast cells expressing PI3K catalytic subunits leads to efficient relocalization of GFP-Akt1 to the plasma membrane, as a consequence of the production of PIP3, and microscopic examination of this phenomenon provides a visual report of the production of PIP3 in individual cells. Remarkably, coexpression of wild-type PTEN in p110-expressing yeast cells efficiently neutralizes all PI3K-induced effects, including PIP3 accumulation and GFP-Akt1 relocalization, as well as cell toxicity. Quantification of the relocalization of GFP-Akt1 on populations expressing mutant versions of p110 and/or PTEN serves as a readout for the oncogenicity of p110 and the tumor suppressor activity of PTEN (Andre´s-Pons et al., 2007) . Activation of Akt1 by p110 in the yeast cell also triggers Akt kinase-dependent toxicity and alterations of the gene expression profile (our unpublished results). Thus, the use of transcriptional reporters could provide additional yeast-based genetic strategies to measure the pathogenicity of mutations in these proteins.
Thanks to the ease of genetic manipulation of the yeast model, the effects of p110 and PTEN can be exploited for several purposes (Figure 4) . First, small molecules can be readily tested as candidate PI3K inhibitors or PTEN modulators, an approach that is easily scalable for high throughput screening. Drugs that are able to efficiently inhibit p110 in vivo but do not display inhibitory effects on other essential cellular functions should allow yeast cells expressing hyperactive p110a to grow, selecting for nontoxic but specific PI3K inhibitors as potential antitumoral compounds. The impermeability of yeast cell wall and the existence of efficient detoxification transporters in yeast may constitute the main caveats for the development of this application (Melese and Hieter, 2002) . The classic PI3K inhibitor wortmannin, for instance, is not able to rescue growth of p110a-CAAX-expressing yeast cells, whereas LY294002 and other commercial inhibitors counteract the effects of p110a-CAAX at sublethal concentrations (our unpublished results). Also, genetic screens based on positive selection of clones that allow yeast growth in the presence of hyperactive p110, could be devised: mutational analyses by in vitro mutagenesis on the sequence of PIK3CA or PTEN genes (see below), either randomly or directed to residues of structural or functional interest, might help mapping essential domains that could define novel targets for the design of inhibitors. Analogously, screen of mammalian cDNA expression libraries in this yeast system could reveal genes that, such as PTEN, act directly on the downregulation of p110 activity or genes that affect PTEN activity in vivo.
The effect of PTEN in rescuing the lack-of-growth phenotype caused by hyperactive p110 is highly specific, as other PIP3 phosphoinositide phosphatases, such as the PIP3 5-phosphatase SHIP1, did not counteract PIP3 production (our unpublished results), in agreement with the notion that yeast is specifically sensitive to PtdIns(4,5)P 2 -PtdIns(3,4,5)P 3 balance. Peculiarly, the S. cerevisiae PTEN ortholog Tep1 did not behave like human PTEN in the yeast reconstitution system (Table 1) (Rodrı´guez-Escudero et al., 2005) , in accor-dance with its reported undetectable catalytic activity (Heymont et al., 2000; Maehama et al., 2001) . Furthermore, a saturated screen for suppressors of p110a-CAAX-induced toxicity with a yeast cDNA expression library did not yield any clone (our unpublished observations), suggesting that S. cerevisiae does not have a PIP3 3-phosphatase activity as efficient as that of human PTEN. Ptn1, the Sch. pombe PTEN ortholog, was also unable to rescue the growth in p110a-CAAXexpressing S. cerevisiae, whereas PTEN from vertebrates (including mouse, frog and zebrafish PTEN) and from insects (fruit fly) were effective in suppressing the p110a-CAAX-induced yeast toxicity (Table 1) . We have taken advantage of this model to perform an extensive mutational analysis on the human PTEN gene, and we have related the pathogenicity of particular PTEN point 
PTEN inhibitory drugs
Genes that negatively regulate PTEN Figure 4 Potential of the yeast model to support studies on the PI3K pathway. (a) Expression of hyperactive mammalian p110 from the regulatable promoter GAL1 (galactose inducible) leads to loss of viability. This can be exploited to screen for PI3K inhibitors, such as small molecules of potential pharmacological interest, or genes whose products block, sequester or impinge a negative regulation on p110 when coexpressed from genomic expression libraries. Also, random in vitro mutagenesis can be performed on the PIK3C genes in search for loss-of-function or gain-of-function mutants. The suppressor and loss-of-function genetic screenings have the technical advantage that selection of clones would be positive. (b) Coexpression of PTEN fully rescues yeast cells from hyperactive p110-imposed toxicity, and the ability of PTEN to counteract PI3K function is related to its tumor suppressor activity. Mutations of clinical origin or artificial mutations generated either randomly or by directly targeting PTEN functional domains can be tested for activity in vivo. Also, screens for PTEN inhibitors can be implemented. In these cases, screening approaches are technically restrained by the need for a negative selection. (c) The binding to membranes of GFP-tagged PKB/Akt produced in p110-expressing cells serves as an in vivo marker of PIP3 production leading to phosphorylation and activation of the Akt kinase. These effects are fully reverted by the presence of wild-type PTEN, but not by PTEN loss-of-function mutants. Thus, monitoring relocation of Akt or using reporters of in vivo Akt activity in this heterologous system is a feasible platform to measure the oncogenicity or tumor suppressor activity of mutations in components of the pathway. Ishioka et al., 1993; Humphrey et al., 1997; Shimodaira et al., 1998; Suzuki et al., 1998) . The fact that the PI3K/PTEN yeast reconstitution system allows the measurement of the reaction products of PI3K and PTEN in vivo makes such system highly sensitive and reliable. Furthermore, random mutagenesis of PTEN in a small-scale screen for loss-of-function mutants allowed the isolation of mutations that mostly coincided to oncogenic mutations described in patients. Working at a larger scale in both directed and random mutagenesis strategies on PTEN would probably contribute to a greater extent to our understanding of the structure-function relation of this tumor suppressor. Nevertheless, important aspects of PTEN regulation, such as those involving their regulatory C2-flexible loop and C-terminal tail, may not be sensed by the yeast system, as PTEN truncated forms lacking these regions behave in yeast similar to the wildtype protein. The appropriate folding and stabilization of PTEN is critical for its tumor suppressor function, as illustrated by the finding that PTEN mutations found in tumors target not only the catalytic activity of the enzyme, but also its stability. Importantly, the stability of PTEN mutants in yeast correlates with its stability in mammalian cells, reinforcing the versatility of the PI3K/ PTEN yeast reconstitution system to predict the pathogenicity of PTEN mutations found in patients.
The study of the functional activity of PTEN mutations in vitro and in mammalian cell systems together with the analysis of PTEN PIP3 catalytic activity and stability in yeast (Georgescu et al., , 2000 Han et al., 2000; Kato et al., 2000; Andre´s-Pons et al., 2007) allows the definition of several categories of PTEN pathogenic mutations with distinctive altered functional properties (Table 2 ). These mutation-specific differences may be relevant for the design of therapies aimed to decrease the enhanced PI3K/Akt signaling that takes place in tumor cells. The combination of PI3K or mTOR inhibitors with proteasome inhibitors or other anticancer drugs (currently in preclinical or clinical use) (Grunwald et al., 2002; Lopiccolo et al., 2008; Marone et al., 2008; Steelman et al., 2008) , or with compounds that could increase moderatelly and/or locally PTEN expression or activity, may cooperate, in some cases, to ameliorate the hyperactivation of the PI3K/PTEN/Akt pathway. In this regard, it is remarkable that several anticancer radiotherapy and chemotherapy treatments (including anti-erbB2, anti-EGFR and anti-g-secretase therapies) rely on PTEN expression and function for efficacy (Nagata et al., 2004; Berns et al., 2007; Frattini et al., 2007; Jiang et al., 2007; Palomero et al., 2007) . The adaptation of versatile and reliable eukaryotic cellular models to the study of the oncogenesis-related PI3K and PTEN pathways should accelerate basic research and provide a platform for the development of diagnostic, prognostic and therapeutic strategies in cancer in the near future. This category may display a dominant negative effect.
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